DR.WU Skincare Co., Ltd. AI Stock Analysis
DR.WU Skincare Co., Ltd. (6523) AI Stock Analysis
DR.WU Skincare Co., Ltd.
(TPEx:6523)
Strong balance sheet, cash flows, and attractive low P/E with high dividend yield are the primary positives supporting the score; weak technical momentum from price below moving averages and negative MACD is the main offset.
DR.WU Skincare Co., Ltd. (6523) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 3.87B
- Dividend Yield
- 12.30%
- Average Volume (3M)
- 27.05K
- Price to Earnings (P/E)
- 12.6
- Beta (1Y)
- 0.16
- Revenue Growth
- -11.85%
- EPS Growth
- -23.46%
- Country
- TW
- Employees
- 150
- Sector
- General
- Sector Strength
- 55
- Industry
- Household & Personal Products
DR.WU Skincare Co., Ltd. Business Overview & Revenue Model
Company Description
Dr. Wu Skincare Co., Ltd. is a company that develops and distributes a broad spectrum of skincare and cosmetic products, serving both the Taiwanese domestic market and an international clientele. Their comprehensive product range includes facial clea...
DR.WU Skincare Co., Ltd. Financial Statement Overview
Summary
High margins, negligible debt, and strong cash conversion indicate robust fundamentals, though recent revenue and profit declines introduce some near-term uncertainty.
Income Statement
62PositiveBalance Sheet
93Very PositiveCash Flow
88Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07B | 1.17B | 1.24B | 1.14B | 926.79M | 1.11B |
| Gross Profit | 717.19M | 805.59M | 878.08M | 814.02M | 658.01M | 694.36M |
| EBITDA | 362.22M | 452.53M | 604.58M | 535.46M | 434.30M | 385.02M |
| Net Income | 297.83M | 350.27M | 476.25M | 424.73M | 339.98M | 296.24M |
Balance Sheet | ||||||
| Total Assets | 1.64B | 1.59B | 1.75B | 1.77B | 1.78B | 1.83B |
| Cash, Cash Equivalents and Short-Term Investments | 1.00B | 836.02M | 908.72M | 1.28B | 1.37B | 1.41B |
| Total Debt | 35.55M | 40.98M | 46.77M | 5.05M | 15.68M | 25.50M |
| Total Liabilities | 370.50M | 235.86M | 294.71M | 291.12M | 254.22M | 296.10M |
| Stockholders Equity | 1.27B | 1.35B | 1.46B | 1.47B | 1.53B | 1.53B |
Cash Flow | ||||||
| Free Cash Flow | 369.44M | 335.01M | 434.43M | 389.16M | 324.24M | 286.23M |
| Operating Cash Flow | 375.22M | 340.92M | 437.18M | 392.44M | 325.83M | 289.60M |
| Investing Cash Flow | 103.39M | 128.40M | -89.21M | -108.64M | -332.73M | 812.05M |
| Financing Cash Flow | -461.05M | -460.49M | -505.36M | -460.47M | -370.21M | -785.36M |
DR.WU Skincare Co., Ltd. Peers Comparison
Overall Rating
TW:670377Outperform
TW:652373Outperform
TW:173071Outperform
TW:443959Neutral
TW:532142Neutral
TW:412040Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 77Outperform | TWD 3.44B | 8.36 | ― | 7.77% | 5.97% | 37.00% | |
| 73Outperform | TWD 3.63B | 12.63 | ― | 12.30% | -11.85% | -23.46% | |
| 71Outperform | TWD 3.19B | 10.48 | ― | 5.95% | 1.66% | 8.74% | |
| 59Neutral | TWD 3.72B | 10.54 | ― | 4.14% | 19.84% | 223.34% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 42Neutral | TWD 3.36B | -17.46 | ― | ― | -21.62% | -494.73% | |
| 40Underperform | TWD 3.85B | -6.75 | ― | 8.91% | 3.77% | -78.32% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6523 | DR.WU Skincare Co., Ltd. | 81.30 | -25.40 | -23.81% | |
| TW:1730 | Farcent Enterprise Co., Ltd. | 50.40 | 0.29 | 0.58% | |
| TW:4120 | Orient Europharma Co., Ltd. | 44.90 | 2.73 | 6.48% | |
| TW:4439 | TST Group Holding Ltd. | 98.00 | 10.91 | 12.53% | |
| TW:5321 | United Recommend International Co., Ltd. | 57.20 | 18.50 | 47.80% | |
| TW:6703 | Shiny Brands Group Co., Ltd. | 94.50 | -1.08 | -1.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
